Vizimpro is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
Banglore: Pfizer Inc informed that its drug to treat a rare form of lung cancer got approval from the U.S. Food and Drug Administration.
The drug, Vizimpro, will look to treat previously untreated patients with a form of metastatic non-small cell lung cancer. VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
The FDA had granted the drug Priority Review designation earlier this year. The status is given to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel)